Medicus Pharma Ltd. has announced a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage drug development company. Under the terms of the agreement, Medicus will acquire all issued and outstanding shares of Antev in exchange for approximately 17% of Medicus's common shares. Antev shareholders are also eligible to receive up to $65 million in additional contingent payments, dependent on future FDA Phase 2 and New Drug Application approvals. The transaction is anticipated to close by the end of August 2025, pending the fulfillment of closing conditions, including Antev shareholder approval. Antev is currently focused on developing Teverelix, a GnRH antagonist, for treating cardiovascular high-risk prostate cancer and acute urinary retention.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.